Rhythm Pharmaceuticals Inc. (RYTM) is seeking FDA approval for the expanded use of Imcivree in treating obesity and controlling hunger in adult and pediatric patients 6 years of age and older with Bardet-Biedl syndrome and Alström syndrome.Bardet-Biedl syndrome and Alström syndrome are ultra-rare genetic diseases, with hyperphagia (insatiable hunger) being a common feature in both of these diseases.Imcivree, a melanocortin-4 receptor agonist, known generically as Setmelanotide, is already approved in the U.S. for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency.The regulatory decision on the proposed expanded indication is expected on June 16, 2022.Imcivree, which became commercially available in the first quarter of 2021, generated sales of $3.2 million for the year ended December 31, 2021.RYTM closed Thursday’s (May 26, 2022) trading at $3.22.